Kemwell Expands Analytical Services Capabilities in India

BANGALORE, May 9, 2013 /PRNewswire/ --

Kemwell Biopharma Pvt. Ltd., a global biopharmaceutical contract development and manufacturing company, announced that it has expanded its analytical capabilities in India to service an FTE contract for a large multinational pharmaceutical company.

Ninad Deshpanday, President of R&D at Kemwell said, "This project and lab expansion further reflects Kemwell's commitment to its customers. Kemwell has invested in a dedicated facility to meet the needs of this very important customer. The scope of the project includes method transfer, stability sample analyses and analytical method validation for various projects for the customer. We are actively looking to invest in and grow our development business."

Today, Kemwell's R&D division employs more than 100 scientists and provides services ranging from formulation development, analytical development and validation to clinical trial manufacturing. The team has experience working on early stage development programs for NCE's, ANDA's, 505 (b) (2) and product life cycle management projects for various customers.

The new analytical lab is equipped with 10 HPLC's, one UPLC and nine dissolution apparatus and other major analytical instruments. Kemwell will employ 15 scientists dedicated for this project.

About Kemwell Biopharma Pvt. Ltd.

Kemwell Biopharma Pvt. Ltd. headquartered in Bangalore, India is a pure-play global contract development and manufacturing company for pharmaceuticals and biopharmaceuticals. The company manufactures and develops products for some of the world's top companies, including AstraZeneca, GlaxoSmithKline, Bayer, Novartis, Merck Group, Boehringer Ingelheim and Pfizer. Kemwell is one of India's largest contract manufacturers with over 30 years' experience. The company employs more than 1000 employees worldwide and has seven production facilities, five in India and two in Sweden. Kemwell is an approved pharmaceutical manufacturer in over 80 countries including the American, European, Japanese and Indian markets.

Read more about Kemwell on www.kemwellbiopharma.com.

Primary Media Contact: Karan Bagaria, [email protected], 91-80-39285450

Secondary Media Contact: Bhaskar Viswanathan, [email protected], 91-80-39285450